Calamos Wealth Management LLC Acquires 20 Shares of McKesson Co. (NYSE:MCK)

Calamos Wealth Management LLC increased its position in shares of McKesson Co. (NYSE:MCK) by 0.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,677 shares of the company’s stock after buying an additional 20 shares during the quarter. Calamos Wealth Management LLC’s holdings in McKesson were worth $2,665,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Wolff Wiese Magana LLC boosted its stake in McKesson by 742.9% in the 3rd quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock worth $29,000 after purchasing an additional 52 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in McKesson in the third quarter worth approximately $29,000. RPg Family Wealth Advisory LLC purchased a new position in McKesson in the 3rd quarter worth $31,000. Synergy Asset Management LLC bought a new stake in shares of McKesson in the 4th quarter valued at about $32,000. Finally, Crews Bank & Trust purchased a new stake in shares of McKesson during the fourth quarter valued at approximately $33,000. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Stock Performance

NYSE MCK opened at $600.43 on Tuesday. The company has a market cap of $76.22 billion, a P/E ratio of 31.09, a P/E/G ratio of 1.29 and a beta of 0.52. The business’s 50 day moving average price is $590.79 and its 200-day moving average price is $561.94. McKesson Co. has a fifty-two week low of $464.42 and a fifty-two week high of $637.51.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.88 by $0.19. The business had revenue of $93.65 billion for the quarter, compared to analysts’ expectations of $89.33 billion. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business’s revenue for the quarter was up 21.3% on a year-over-year basis. During the same quarter last year, the firm earned $6.23 EPS. As a group, equities analysts predict that McKesson Co. will post 32.72 EPS for the current year.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, March 3rd. This represents a $2.84 annualized dividend and a yield of 0.47%. McKesson’s dividend payout ratio is presently 14.71%.

Insiders Place Their Bets

In other McKesson news, EVP Leann B. Smith sold 579 shares of McKesson stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the transaction, the executive vice president now directly owns 864 shares of the company’s stock, valued at $494,890.56. The trade was a 40.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.11% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

MCK has been the subject of a number of research analyst reports. Leerink Partners dropped their price target on McKesson from $665.00 to $630.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Bank of America dropped their price target on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. StockNews.com raised McKesson from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Baird R W raised shares of McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Finally, Citigroup lowered their target price on shares of McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a report on Friday, January 10th. Two analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.